1,560 results match your criteria Esophageal Lymphoma

Change in cancer diagnosis during the COVID-19 pandemic: Trends estimated from FDG-PET/CT.

Glob Health Med 2022 Apr;4(2):108-115

Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.

The aim of this study is to clarify changes in the circumstances of cancer diagnoses during the COVID-19 pandemic in Tokyo, Japan, estimated from [F]-2-fluoro-2-deoxy-D-glucose (FDG) -positron emission tomography/ computed tomography (PET/CT) for cancer patients. Cancer diagnosis in pandemic status (PANS) was evaluated by retrospective review of the findings of FDG-PET/CT examinations performed between 11 March 2020 and 28 December 2021 for initial staging and restaging for malignancy. Evaluation of cancer diagnosis in pre-pandemic status (pPANS) was conducted similarly in FDG-PET/CT examinations performed between 4 January 2018 and 10 March 2020. Read More

View Article and Full-Text PDF

Optical Coherence Tomography Evaluation of Carotid Artery Stenosis and Stenting in Patients With Previous Cervical Radiotherapy.

Front Neurosci 2022 27;16:861511. Epub 2022 Apr 27.

Department of Neurology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.

Objectives: Cervical radiotherapy can lead to accelerated carotid artery stenosis, increased incidence of stroke, and a higher rate of in-stent restenosis in irradiated patients. Our objective was to reveal the morphological characteristics of radiation-induced carotid stenosis (RICS) and the stent-vessel interactions in patients with previous cervical radiotherapy by optical coherence tomography (OCT).

Materials And Methods: Between November 2017 and March 2019, five patients with a history of cervical radiotherapy were diagnosed with severe carotid artery stenosis and underwent carotid artery stenting (CAS). Read More

View Article and Full-Text PDF

Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.

Front Endocrinol (Lausanne) 2022 14;13:846357. Epub 2022 Apr 14.

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group with varied pathophysiological, genetic, and clinical features, accounting for approximately one-third of all lymphoma cases worldwide. Notwithstanding that unprecedented scientific progress has been achieved over the years, the survival of DLBCL patients remains low, emphasizing the need to develop novel prognostic biomarkers for early risk stratification and treatment optimization.

Method: In this study, we screened genes related to the overall survival (OS) of DLBCL patients in datasets GSE117556, GSE10846, and GSE31312 using univariate Cox analysis. Read More

View Article and Full-Text PDF

Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study.

Anticancer Res 2022 May;42(5):2783-2790

Department of Gastroenterological Surgery, Kanazawa University, Kanazawa, Japan.

Background/aim: To evaluate the impact of prophylactic administration of pegfilgrastim in esophageal cancer (EC) patients treated with chemotherapy consisted of docetaxel, cisplatin, and fluorouracil (DCF).

Patients And Methods: Among 102 patients who received neoadjuvant or induction DCF for primary advanced EC, 65 received prophylactic pegfilgrastim and 37 did not. The association of pegfilgrastim with adverse events and clinicopathological outcomes was retrospectively analyzed. Read More

View Article and Full-Text PDF

LncRNA SBF2-AS1: A Budding Star in Various Cancers.

Curr Pharm Des 2022 Apr 18. Epub 2022 Apr 18.

Third-grade Pharmacological Laboratory on Traditional Chinese Medicine,State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.

Long non-coding RNA (lncRNA) is a new kind of RNA with lengths over 200 nucleotides. Current frontiers revealed that lncRNAs implicate in various tumor progression, including tumorigenesis, proliferation, migration, invasion, metastasis and angiogenesis. Recently discovered long non-coding RNA SET-binding factor 2 antisense RNA 1 (lncRNA SBF2-AS1), an oncogenic antisense RNA to SBF2, locates at 11p15. Read More

View Article and Full-Text PDF

The potential efficacy and mechanism of bendamustine in entra-nodal NK/T cell lymphoma.

Hematol Oncol 2022 Apr 19. Epub 2022 Apr 19.

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.

Bendamustine has been shown to have anti-tumor activities in hematological malignancies, but the role of bendamustine in natural killer (NK)/T cell lymphoma (NKTCL) treatment is unclear. Our study has shown that bendamustine had potent growth-inhibitory and apoptosis-inducing effects on NKTCL cells. Interestingly, we noticed that the combination of either gemcitabine or etoposide results in additive or synergistic cytotoxicity. Read More

View Article and Full-Text PDF

Multifunctional nanoparticles co-loaded with Adriamycin and MDR-targeting siRNAs for treatment of chemotherapy-resistant esophageal cancer.

J Nanobiotechnology 2022 Mar 28;20(1):166. Epub 2022 Mar 28.

Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

The development of multidrug resistance (MDR) during cancer chemotherapy is a major challenge in current cancer treatment strategies. Numerous molecular mechanisms, including increased drug efflux, evasion of drug-induced apoptosis, and activation of DNA repair mechanisms, can drive chemotherapy resistance. Here we have identified the major vault protein (MVP) and the B-cell lymphoma-2 (BCL2) gene as two potential factors driving MDR in esophageal squamous cell carcinoma (ESCC). Read More

View Article and Full-Text PDF

Endoscopic and pathologic motifs for the clinical diagnosis of Epstein-Barr virus-associated gastric cancer.

DEN open 2021 Apr 21;1(1):e7. Epub 2021 Apr 21.

Department of Laboratory Science Graduate School of Medicine, Yamaguchi University Yamaguchi Japan.

Objectives: Based on the recent therapeutic trends for gastric cancer (GC), the clinical impact of the diagnosis of Epstein-Barr virus (EBV)-associated GC (EBVaGC) appears to be important. We retrospectively analyzed endoscopic and pathologic motifs of GC lesions to narrow the number of candidates for EBV testing.

Methods: We performed EBV tests for 32 upper gastrointestinal lesions of 32 patients in the clinical setting. Read More

View Article and Full-Text PDF

Screening and verification of potential gene targets in esophageal carcinoma by bioinformatics analysis and immunohistochemistry.

Ann Transl Med 2022 Jan;10(2):70

Department of Gastroenterology, Meizhou People's Hospital, Meizhou, China.

Background: To evaluate the potential of candidate proteins as diagnostic markers or drug targets in esophageal carcinoma (ESCA).

Methods: GSE20347, GSE17351, and GSE45670 were downloaded from Gene Expression Omnibus (GEO). Differently expressed genes (DEGs) between ESCA and normal esophageal tissues from patients were obtained. Read More

View Article and Full-Text PDF
January 2022

Characterization of Desmoglein 3 (DSG3) as a Sensitive and Specific Marker for Esophageal Squamous Cell Carcinoma.

Gastroenterol Res Pract 2022 24;2022:2220940. Epub 2022 Feb 24.

Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.

Although P40 and P63 are both sensitive and specific for routine esophageal squamous cell carcinoma (SCC) diagnosis, we recently showed that P40 and P63 immunoreactivities were significantly lower in well-differentiated SCC than those in higher grade tumors. Therefore, a novel esophageal SCC marker, ideally performing better in well-differentiated SCC, is still needed. We characterized desmoglein 3 (DSG3) immunohistochemistry in esophageal SCC, esophageal adenocarcinoma, small-cell lung carcinoma, and large B-cell lymphoma, alongside P40 and CK5/6. Read More

View Article and Full-Text PDF
February 2022

Lack of Cardiotoxicity Endpoints in Prospective Trials Involving Chest Radiation Therapy: A Review of Registered, Latter-Phase Studies.

Front Oncol 2022 9;12:808531. Epub 2022 Feb 9.

Department of Radiation Oncology at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.

Background: Chest radiation therapy (RT) has been associated with increased cardiac morbidity and mortality in numerous studies including the landmark Darby study published in 2013 demonstrating a linear increase in cardiac mortality with increasing mean heart radiation dose. However, the extent to which cardiotoxicity has been incorporated as an endpoint in prospective RT studies remains unknown.

Methods: We queried clincaltrials. Read More

View Article and Full-Text PDF
February 2022

Cardiovascular Event Reporting in Modern Cancer Radiation Therapy Trials.

Adv Radiat Oncol 2022 Mar-Apr;7(2):100888. Epub 2021 Dec 29.

Cardio-Oncology Program, Division of Cardiology, Ohio State University Medical Center, Columbus, Ohio.

Purpose: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in cancer survivors, particularly after chest radiation therapy (RT). However, the extent to which CVD events are consistently reported in contemporary prospective trials is unknown.

Methods And Materials: From 10 high-impact RT, oncology, and medicine journals, we identified all latter phase trials from 2000 to 2019 enrolling patients with breast, lung, lymphoma, mesothelioma, or esophageal cancer wherein chest-RT was delivered. Read More

View Article and Full-Text PDF
December 2021

Unrecognized thoracic radiotherapy toxicity: A review of literature.

Cancer Radiother 2022 Feb 10. Epub 2022 Feb 10.

LaTIM, INSERM, UMR 1101, University of Brest, 29200, Brest, France.

Radiotherapy remains an important treatment modality for patients with chest malignancies; this is particularly true in patients with breast cancer and Hodgkin lymphoma as well as lung, esophageal, and other mediastinal tumors. More than half of patients with these conditions receive radiotherapy at some point. With the development of new treatment modalities, we are witnessing an improvement of overall survival requiring carefully watching of acute and chronic toxicity of radiation therapy. Read More

View Article and Full-Text PDF
February 2022

Detection of a second primary cancer in a 18F-fluorocholine PET/CT - multicentre retrospective analysis on a group of 1345 prostate cancer patients.

Nucl Med Rev Cent East Eur 2022 ;25(1):25-30

Department of Nuclear Medicine, Affidea Poznan, Poland.

Background: Aim of this study was to evaluate the rate of incidental detection of second primary cancer (SPC) at 18F-fluorocholine ([18F]FCH) positron emission tomography/computed tomography (PET/CT) performed in prostate cancer patients.

Material And Methods: A retrospective analysis was performed on a group of 1345 prostate cancer patients, who underwent [18F]FCH PET/CT study because of suspicion of recurrence (n = 937) or for initial staging (n = 408). Images were acquired after intravenous injection [18F]FCH with a mean activity of 200 ± 75 MBq (5. Read More

View Article and Full-Text PDF
February 2022

Expression patterns and clinical significances of PBK in lung cancer: an analysis based on Oncomine database.

Jinglei Li Wei Hou

Transl Cancer Res 2021 May;10(5):2036-2043

Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Background: Based on both biological and clinical perspectives, lung cancer is a diverse disease with varied histological subtypes. At present, molecular-targeted drugs have broad application prospects in lung cancer clinical therapy. Here, we explored the expression profile of PDZ-binding kinase (PBK) in lung cancer along with its prognostic potential. Read More

View Article and Full-Text PDF

The diagnostic significance of 64-slice spiral CT combined with serological CA19-9, Bcl-2, CYFRA21-1 detection in thoracic esophageal carcinoma.

Transl Cancer Res 2021 Dec;10(12):5383-5389

Department of Oncology, Dazu District People's Hospital, Chongqing, China.

Background: To analyze the clinical value of multi-slice spiral computed tomography (MSCT) combined with carbohydrate antigen 19-9 (CA19-9), B-cell leukemia/lymphoma-2 protein (Bcl-2), and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) detection in the diagnosis of thoracic esophageal cancer.

Methods: The clinical data of 74 patients with thoracic esophageal cancer admitted to the Dazu District People's Hospital in Chonqing, China, from December 2019 to December 2020 were collected (esophageal cancer group), and their computed tomography (CT) signs were analyzed. Another 55 healthy people who underwent physical examination during the same period in the hospital were selected for the healthy group. Read More

View Article and Full-Text PDF
December 2021

Patient Reported Outcomes in Metastatic Spine Disease: Concurrent Validity of PROMIS with the Spine Oncology Study Group Outcome Questionnaire.

Spine (Phila Pa 1976) 2022 Apr 31;47(8):591-596. Epub 2022 Jan 31.

University of Rochester Medical Center, Department of Orthopaedics & Physical Performance, Rochester, NY.

Study Design: Cross-sectional prospective study.

Objective: To evaluate the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF), Pain Interference (PI), and Depression domains in comparison to the Spine Oncology Study Group-Outcomes Questionnaire (SOSG-OQ) in patients with metastatic spine disease.

Summary Of Background Data: While there remains a significant movement toward incorporating patient-reported outcome measures (PROMs) into clinical care, there are few validated PROMs for patients with metastatic spine disease. Read More

View Article and Full-Text PDF

Mitosis-related gene as a potential biomarker in malignancy.

Ann Transl Med 2021 Dec;9(23):1744

Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.

Background: Centromere protein U () is a component of the kinetochore and can regulate the cell cycle as a receptor of polo-like kinase 1 (). Recent studies have partially identified the role of in tumor progression, but the underlying mechanisms of in tumor immunity remain obscure.

Methods: We performed pan-cancer analysis to evaluate the role of in immunity and proliferation with data from The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE) datasets, and Genotype-Tissue Expression (GTEx) project. Read More

View Article and Full-Text PDF
December 2021

Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts.

Comput Struct Biotechnol J 2022 7;20:496-507. Epub 2022 Jan 7.

Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.

Background: Cox proportional hazard regression (CPH) model relies on the proportional hazard (PH) assumption: the hazard of variables is independent of time. CPH has been widely used to identify prognostic markers of the transcriptome. However, the comprehensive investigation on PH assumption in transcriptomic data has lacked. Read More

View Article and Full-Text PDF
January 2022

Radiation-Induced Heart Disease.

J Clin Med 2021 Dec 28;11(1). Epub 2021 Dec 28.

Department of Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.

Cancer incidence and survivorship have had a rising tendency over the last two decades due to better treatment modalities. One of these is radiation therapy (RT), which is used in 20-55% of cancer patients, and its basic principle consists of inhibiting proliferation or inducing apoptosis of cancer cells. Classically, photon beam RT has been the mainstay therapy for these patients, but, in the last decade, proton beam has been introduced as a new option. Read More

View Article and Full-Text PDF
December 2021

A Case of Esophageal Plasmablastic Lymphoma With a Literature Review.

Cureus 2021 Nov 17;13(11):e19664. Epub 2021 Nov 17.

Gastroenterology, Ascension St. John Hospital, Detroit, USA.

Plasmablastic lymphoma is a rare B-cell lymphoma that is mainly associated with immunocompromised patients, such as those affected with human-immunodeficiency virus (HIV) or those who have received solid organ transplants; however, it has also been documented in immunocompetent patients. Moreover, there is also a strong association with Epstein-Barr virus (EBV). Although mainly found in the oral cavity, a few cases were documented to affect the gastrointestinal tract, and of those, only three cases were found to involve the esophagus, and we present the fourth case in a 48-year-old HIV-positive male. Read More

View Article and Full-Text PDF
November 2021

[Sjogren's disease/syndrome in combination with autoimmune liver damage. 20-years observation].

Stomatologiia (Mosk) 2021 ;100(6):108-114

ANPO «Sjogren-No», Moscow, Russia.

Sjogren's disease (BS) is a systemic autoimmune disease, the main symptoms of which are associated with dry eyes, mouth, skin, respiratory and gastrointestinal tract, etc., but there are a large number of extra-vascular symptoms that can accompany this disease: weakness, swelling of the lymph nodes, respiratory failure, pain and swelling of the joints, rash, dysphagia, gastro-esophageal reflux, lymphoma, etc. In addition, the etiology of this disease remains unknown, and the pathogenesis is partially studied. Read More

View Article and Full-Text PDF
December 2021

RFLMDA: A Novel Reinforcement Learning-Based Computational Model for Human MicroRNA-Disease Association Prediction.

Biomolecules 2021 12 5;11(12). Epub 2021 Dec 5.

Jiangsu Province Key Laboratory of Intelligent Building Energy Efficiency, Suzhou University of Science and Technology, Suzhou 215009, China.

Numerous studies have confirmed that microRNAs play a crucial role in the research of complex human diseases. Identifying the relationship between miRNAs and diseases is important for improving the treatment of complex diseases. However, traditional biological experiments are not without restrictions. Read More

View Article and Full-Text PDF
December 2021

Clinical impact of Fn-induced high expression of KIR2DL1 in CD8 T lymphocytes in oesophageal squamous cell carcinoma.

Ann Med 2022 Dec;54(1):51-62

Anyang Tumor Hospital (The Fourth Affiliated Hospital of Henan University of Science and Technology), Anyang, Henan, China.

Background: To analyze the correlation between the inducing effect of (Fn) on the surface expression of the inhibitory receptor KIR2DL1 on CD8 T cells in oesophageal squamous cell carcinoma (ESCC) and the clinicopathological features and survival prognosis and to explore its clinical significance.

Methods: The inducing effect of Fn on CD8 T cell surface inhibitory receptor KIR2DL1 expression was analyzed in a coculture system of human CD8 T cells and ESCC cells infected with Fn. Fn infection and the expression of KIR2DL1 on CD8 T cells were detected by RNAscope and immunohistochemistry in ESCC tissues, and the correlations between the inducing effect of Fn on KIR2DL1 expression on CD8 T cells and clinicopathological features were analyzed. Read More

View Article and Full-Text PDF
December 2022

Primary gastrointestinal anaplastic large cell lymphoma: A critical reappraisal with a systematic review of the world literature.

J Cancer Res Ther 2021 Oct-Dec;17(6):1307-1313

Deprtment of Medical Oncology/Hematology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.

Anaplastic large cell lymphoma (ALCL) is a distinct T-cell non-Hodgkin lymphoma involving both nodal and extra-nodal sites with a specific anaplastic lymphoma kinase 1 (ALK-1) gene rearrangement. The commonly involved extranodal sites include skin, bone, soft tissue, lungs, and liver. ALCL primarily involving gastrointestinal (GI) tract is rare. Read More

View Article and Full-Text PDF

[Naringin inhibits the proliferation and invasion of Eca109 esophageal cancer cells and promotes its apoptosis by blocking JAK/STAT signal pathway].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2021 Dec;37(12):1085-1091

Department of Hepatobiliary Surgery, Baoji Central Hospital, Baoji 721001, China. *Corresponding author, E-mail:

Objective To investigate the inhibitory effect of naringin (NAR) on proliferation and apoptosis of Eca109 esophageal cancer cells and its mechanism. Methods Eca109 cells were cultured with 0, 15, 30, 45 μmol/L NAR treatment for 24, 48 and 72 hours. The colony forming ability of Eca109 esophageal cancer cells was evaluated by cell colony forming assay, the cell proliferation activity was detected by MTT assay, and the invasion ability of cancer cells was detect by Transwell assay; Apoptosis was detected by annexin V-FITC/PI double labeling combined with flow cytometry. Read More

View Article and Full-Text PDF
December 2021

Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system.

Transl Lung Cancer Res 2021 Oct;10(10):3865-3874

Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Background: The American Society for Clinical Oncology recently launched the minimal common oncology data elements project to facilitate cancer data interoperability. However, clinical data are often unrecorded in an organized way, and converting them into a structured format can be time-consuming. Clinical Data Warehouse (CDW) is a database that consolidates data from different clinical sources. Read More

View Article and Full-Text PDF
October 2021

Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma.

Hematol Oncol 2021 Dec 1. Epub 2021 Dec 1.

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Natural killer/T cell lymphoma (NKTCL) is a highly aggressive hematological malignancy. However, there is currently no consensus on therapies for refractory/relapsed patients. In this study, we investigated the synergistic anticancer effect and potential mechanism of combining chidamide, a histone deacetylases (HDACs) inhibitor, and etoposide, a DNA-damaging agent, in NKTCL. Read More

View Article and Full-Text PDF
December 2021

Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.

Cancer Immunol Immunother 2021 Nov 24. Epub 2021 Nov 24.

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, 100021, China.

Background: Antibodies targeting programmed cell death-1(PD1) and its ligand (PDL1) have revolutionized cancer therapy. However, little is known about the preexisted anti-PD1/PDL1 autoantibodies (AAbs) distribution in multiple cancer types, nor is their potential biomarker role for anti-PD1 therapy.

Method: Plasma anti-PD1/PDL1 AAb IgG and subclasses (IgG1-4) were detected by enzyme-linked immune sorbent assay (ELISA) in 190 cancer patients, covering 10 cancer types (lung, breast, esophageal, colorectal, liver, prostatic, cervical, ovarian, gastric cancers and lymphoma), the comprehensive correlation of AAbs with multiple clinical parameters was analyzed. Read More

View Article and Full-Text PDF
November 2021

Pitfalls in gastrointestinal tract haematopoietic lesions.

Pathology 2022 Mar 18;54(2):177-183. Epub 2021 Nov 18.

Department of Pathology, Division of Hematopathology, Division of Gastrointestinal Pathology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, and Jackson Memorial Hospital, Miami, FL, USA. Electronic address:

Specimens from the gastrointestinal (GI) tract are among the most commonly encountered in routine pathology practice worldwide. It is well known that the luminal GI tract is home to various areas rich in mucosa-associated lymphoid tissue (MALT), whether native or acquired. The latter may be particularly problematic due to its well-known predisposing factors such as Helicobacter pylori infection and autoimmune conditions. Read More

View Article and Full-Text PDF